Systemic therapy is often given late due to optimism bias, treatment momentum, and difficulty in end-of-life conversations, leading to increased hospitalizations and ICU admissions. MD Anderson Cancer ...

Serial metastasis-directed radiotherapy extended time off systemic therapy while maintaining favorable progression-free and overall survival in patients with oligometastatic clear-cell renal cell ...

Hepatocellular carcinoma (HCC) management is rapidly evolving as systemic therapies and locoregional treatments are increasingly combined across disease ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for ...

Stereotactic body radiotherapy (SBRT) alone achieves a 69.7% pooled 1- or 2-year systemic therapy-free survival rate across cancer types, with the highest rates seen in renal cell and prostate cancers ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

Fig 1. Summary of key guideline recommendations. ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibitor; C, conditional; CRPC, castration ...